None listed
Conditions
Interventions
None listed
Sponsors
National Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults aged 65 years or older who have provided written informed consent to participate in the study. Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the 2018 iwCLL diagnostic criteria. Patients expected to initiate BTK inhibitor monotherapy within 60 days after enrollment in this study. Patients with an expected life expectancy of at least 6 months at the time of enrollment.
Exclusion criteria
Exclusion criteria: Patients with monoclonal B-cell lymphocytosis or small lymphocytic lymphoma who do not meet the iwCLL diagnostic criteria for chronic lymphocytic leukemia (CLL). Patients who have previously received any treatments for CLL other than BTK inhibitors, or those receiving BTK inhibitors in combination with other agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival, PFS | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival, OS;Objective Response Rate, ORR;Minimal Residual Disease Negativity Rate;Adverse Events, AE | — |
Countries
Korea, Republic of
Contacts
Public ContactJongheon Jung
National Cancer Center
Outcome results
None listed